U.S. pharma giant copyright scrapped two experimental weight loss pills final calendar year—a after-everyday tablet, lotiglipron, because of elevated liver enzymes plus a 2 times-day-to-day capsule, danuglipron, because of sturdy Unintended effects—but CEO Albert Bourla has claimed t